• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Aktis Oncology, Inc. - Common stock (NQ:AKTS)

    26.16 +0.59 (+2.29%)
    Streaming Delayed Price Updated: 11:26 AM EDT, Jul 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 359,170
    Open 25.91
    Bid (Size) 26.07 (100)
    Ask (Size) 26.28 (100)
    Prev. Close 25.58
    Today's Range 25.32 - 26.88
    52wk Range 14.72 - 34.19
    Shares Outstanding 51,310,014
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Aktis Oncology to Present at the Jefferies Global Healthcare Conference
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
    From Aktis Oncology Inc.
    Via GlobeNewswire

    Performance

    YTD
    +16.8%
    +16.8%
    1 Month
    +26.5%
    +26.5%
    3 Month
    +50.9%
    +50.9%
    6 Month
    +20.3%
    +20.3%
    1 Year
    +16.8%
    +16.8%

    More News

    Read More
    News headline image
    Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology to Present at the BofA Securities Health Care Conference
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology to Present at Upcoming March Investor Conferences
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market
    Via MarketMinute
    Topics Artificial Intelligence ETFs Initial Public Offering
    MarketBeat Week in Review – 01/12 - 01/16 ↗
    Via MarketBeat
    News headline image
    A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗
    Via MarketBeat
    Topics Initial Public Offering
    News headline image
    Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Aktis Oncology Inc.
    Via GlobeNewswire
    News headline image
    12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Crude Oil Down 1%; Webuy Global Shares Spike Higher ↗
    Via Benzinga
    News headline image
    Nasdaq Surges Over 100 Points; NY Empire State Manufacturing Index Dips In December ↗
    Via Benzinga
    News headline image
    Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
    From Akoustis, Inc.
    Via GlobeNewswire
    News headline image
    Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
    From Akoustis, Inc.
    Via Business Wire
    News headline image
    12 Information Technology Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Why Uxin Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    12 Information Technology Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Information Technology Stocks Moving In Thursday's Pre-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Aktis Oncology, Inc. - Common stock publicly traded?
    Yes, Aktis Oncology, Inc. - Common stock is publicly traded.
    What exchange does Aktis Oncology, Inc. - Common stock trade on?
    Aktis Oncology, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Aktis Oncology, Inc. - Common stock?
    The ticker symbol for Aktis Oncology, Inc. - Common stock is AKTS on the Nasdaq Stock Market
    What is the current price of Aktis Oncology, Inc. - Common stock?
    The current price of Aktis Oncology, Inc. - Common stock is 26.16
    When was Aktis Oncology, Inc. - Common stock last traded?
    The last trade of Aktis Oncology, Inc. - Common stock was at 07/14/26 11:26 AM ET
    What is the market capitalization of Aktis Oncology, Inc. - Common stock?
    The market capitalization of Aktis Oncology, Inc. - Common stock is 1.34B
    How many shares of Aktis Oncology, Inc. - Common stock are outstanding?
    Aktis Oncology, Inc. - Common stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.